Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril [amount hidden] on blood pressure and neurohormonal effects in salt-deplete man

What Was Tested

Researchers studied Angiotensin II in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

The researchers also evaluated safety and tolerability.

Sixteen healthy, normotensive male volunteers followed a standardised salt-depletion regimen for 3 days before each study day.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Angiotensin II, giving a reference point.

Supine and erect blood pressure (BP) and heart rate (HR); serum and urinary electrolytes; plasma active renin (PAR), aldosterone, and Ang II were measured at intervals.

What Was Measured

The researchers also evaluated safety and tolerability.

PubMed files the paper under topics including Aldosterone, Angiotensin II, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Creatinine and Diet, Sodium-Restricted.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in people with low blood pressure and orthostatic hypotension.

The publication is from 1995 (Journal of cardiovascular pharmacology), a journal based in United States.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.